• If you are wondering whether Supernus Pharmaceuticals at around US$55.09 is still offering value after its recent run, you are not alone.
• The stock has posted returns of 8.7% over the past 7 days, 14.4% over 30 days, 11.4% year to date and 73.6% over 1 year, with longer term returns of 43.5% over 3 years and 116.0% over 5 years.
• These moves sit against a backdrop of continuing interest in Supernus Pharmaceuticals as a neurology focused drug maker. Investors are paying close attention to how its product portfolio and pipeline position it in the wider pharmaceuticals and biotech sector. This article is not tied to a specific headline; instead, it aims to give ongoing context for readers tracking the stock beyond short term news flow.
• Right now, Supernus Pharmaceuticals scores a 4 out of 6 valuation checks. This suggests there is more to unpack when you compare different methods such as multiples and cash flow based models. Later in the article we will look at an even more rounded way to think about what the market is pricing in.

Approach 1: Supernus Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value, aiming to estimate what the entire business could be worth right now.

For Supernus Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $71.1 million. Analyst inputs and further extrapolated estimates feed into ten year projections, which include forecast free cash flow of $477.1 million in 2030, with intermediate years such as 2026 at $133.4 million and 2028 at $345.6 million. Simply Wall St applies its own assumptions beyond the analyst horizon to complete the later years of the model.

When all those future cash flows are discounted back and summed, the estimated intrinsic value comes out at about $198.54 per share. Compared with the current share price of around $55.09, the model suggests Supernus Pharmaceuticals is trading at a 72.3% discount on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Supernus Pharmaceuticals is undervalued by 72.3%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Approach 2: Supernus Pharmaceuticals Price vs Sales

For companies where revenue is a key driver and earnings can be influenced by accounting items or investment in research, the P/S ratio is often a useful way to compare what the market is paying for each dollar of sales.

Higher growth expectations or lower perceived risk can justify a higher P/S ratio, while slower expected growth or higher risk typically point to a lower “normal” multiple. That is why it helps to look at where a stock sits relative to its sector and peers.

Supernus Pharmaceuticals currently trades on a P/S of 4.40x. This is close to the broader Pharmaceuticals industry average of 4.17x and sits well below the peer group average of 16.06x. Simply Wall St also provides a “Fair Ratio” estimate of 5.87x, which reflects factors such as earnings growth, profit margins, size, industry and company specific risks.

This Fair Ratio can be more tailored than a simple peer or industry comparison, because it blends those broader benchmarks with Supernus Pharmaceuticals own fundamentals. With the current P/S of 4.40x below the Fair Ratio of 5.87x, the multiple based view points to the shares being undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Supernus Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Supernus Pharmaceuticals to numbers by telling a clear story about future revenue, earnings, margins and a fair value. You can then compare that fair value to today’s price. Each Narrative sits on the Community page and updates automatically when fresh news or earnings arrive. One investor might build a more optimistic story closer to the US$45 analyst target, while another leans toward the US$36 view. You can see exactly how each storyline, and its forecast, leads to a different conclusion about whether the current price looks high or low.

Do you think there's more to the story for Supernus Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.